Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Income Before Tax
Profit after all operating and non-operating items but before income tax.
Income Before Tax history
Currency unavailable · from the income statement
No Income Before Tax data reported for this period type.
Income Before Tax vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.17M USD | — | — | — |
| LTM Mar 2026 | -$56.41M USD | -34.0% | — | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$58.44M USD | -17.3% | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$107.28M USD | -34.6% | — | 536.4% |
| LTM Mar 2026 | -$149.7M USD | -169.1% | — | 68.7% | |
| LTM Mar 2026 | -$199.48M USD | -146.3% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$222.34M USD | +13.7% | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -34.3% | — | 302.6% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.